Exhibit 99.1 CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer's disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflam ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-37942 CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware 30-0645032 (State o ...

LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: CervoMed Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with Leerink Partners LLC (the "Agent"), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent up to $50,000,000 of shares of common stock, ...

Financial Position - The company has approximately $35.2 million in cash and cash equivalents and marketable securities as of March 31, 2025[116]. - The accumulated deficit as of March 31, 2025, is $75.6 million, with a net loss of $4.9 million for the three months ended March 31, 2025, compared to a net loss of $2.5 million for the same period in 2024, representing a 95% increase in loss[117][128]. - Interest income for the three months ended March 31, 2025, was $0.4 million, a 407% increase from $0.1 million in the same period in 2024, due to higher cash equivalents and marketable securities[133]. - Total operating expenses for the three months ended March 31, 2025, were $7.2 million, a 46% increase from $4.9 million in the same period in 2024[128]. - For the three months ended March 31, 2025, net cash used in operating activities was $3.9 million, compared to $1.4 million for the same period in 2024[140][142]. - Cash used in investing activities for the three months ended March 31, 2025, was $5.4 million due to the purchase of marketable securities[144]. - The net cash outflow from operations for the three months ended March 31, 2025, was primarily due to a net loss of $4.9 million[141]. - The company has no off-balance sheet arrangements that could materially affect its financial condition[148]. Research and Development - Research and development expenses increased by 72% to $4.8 million for the three months ended March 31, 2025, compared to $2.8 million for the same period in 2024, primarily due to increased clinical trial costs[130]. - The company is conducting the RewinD-LB Trial, a Phase 2b study involving 159 participants with DLB, funded primarily by a $21.3 million grant from the NIA[114]. - The company plans to initiate a Phase 2 trial (Restore Trial) evaluating neflamapimod in up to 90 participants recovering from ischemic stroke in Q2 2025[115]. - The company expects to report 32-week results from the Extension of the RewinD-LB Trial in the second half of 2025 and plans to meet with the FDA to discuss Phase 3 plans thereafter[114]. - The company anticipates continued increases in research and development expenses, general and administrative expenses, and capital expenditures[137]. Capital Needs - The company has never been profitable and will continue to require additional capital for the foreseeable future to develop neflamapimod[117]. - The company expects to finance its cash needs through equity offerings, debt financings, or other capital sources, including collaborations and licenses[138]. - The company may need additional funds to advance product candidates through clinical development and to fund operations[138]. - As of March 31, 2025, the company believes its existing cash and cash equivalents will fund operations for at least twelve months[138]. - The company completed a private placement on April 1, 2024, raising approximately $50.0 million, with potential additional proceeds of up to $99.4 million from Series A Warrants[135].